{
    "2021-03-18": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Top Analyst Reports for Novo Nordisk, NextEra & 3M Company",
                "features": {
                    "keywords": [
                        "analyst reports",
                        "Novo Nordisk",
                        "NextEra",
                        "3M"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "industrial"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-04-20",
                "original_text": "Gilead, Novo Nordisk Expand NASH Collaboration",
                "features": {
                    "keywords": [
                        "Gilead",
                        "Novo Nordisk",
                        "NASH",
                        "collaboration"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-05-10",
                "original_text": "Gilead, Novo Nordisk To Test Triple Combo Therapy In New NASH Study",
                "features": {
                    "keywords": [
                        "Gilead",
                        "Novo Nordisk",
                        "triple combo therapy",
                        "NASH",
                        "study"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-06-05",
                "original_text": "Gilead and Novo Nordisk Expand NASH Clinical Collaboration",
                "features": {
                    "keywords": [
                        "Gilead",
                        "Novo Nordisk",
                        "NASH",
                        "clinical collaboration"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}